| 1 | The impact of chronic pain on brain gene expression | | | | |
|----------------|---|--|--|--|--|
| 2 | | | | | |
| 3 | Lily Collier ^{1,2} , Carina Seah ³ , Emily M. Hicks ³ , Traumatic Stress Brain Research Group, | | | | |
| 4 | Paul E. Holtzheimer ^{4,5} , John H. Krystal ^{2,6} , Matthew J. Girgenti ^{2,6} , Laura M. Huckins ² *, | | | | |
| 5 | Keira J.A. Johnston ² * | | | | |
| 6 | | | | | |
| 7 | 1. Department of Biological Sciences, Columbia University, New York City, NY | | | | |
| 8 9 | 2. Department of Psychiatry, Division of Molecular Psychiatry, Yale University, New Haven, CT | | | | |
| 10 11 | 3. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY | | | | |
| 12 | 4. National Center for PTSD, U.S. Department of Veterans Affairs | | | | |
| 13 14 | Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA | | | | |
| 15 16 17 | Clinical Neuroscience Division, National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT | | | | |
| 18 | Abstract | | | | |
| 19 | Background: Chronic pain affects one fifth of American adults, contributing significant public | | | | |
| 20 | health burden. Chronic pain mechanisms can be further understood through investigating brain | | | | |
| 21 | gene expression. Methods: We tested differentially expressed genes (DEGs) in chronic pain, | | | | |
| 22 | migraine, lifetime fentanyl and oxymorphone use, and with chronic pain genetic risk in four | | | | |
| 23 | brain regions (dACC, DLPFC, MeA, BLA) and imputed cell type expression data from 304 | | | | |
| 24 | postmortem donors. We compared findings across traits and with independent transcriptomics | | | | |
| 25 | resources, and performed gene-set enrichment. Results: We identified two chronic pain DEGs: | | | | |
| 26 | B4GALT and VEGFB in bulk dACC. We found over 2000 (primarily BLA microglia) chronic | | | | |
| 27 | pain cell type DEGs. Findings were enriched for mouse microglia pain genes, and for hypoxia | | | | |
| 28 | and immune response. Cross-trait DEG overlap was minimal. Conclusions: Chronic pain- | | | | |
| 29 | associated gene expression is heterogeneous across cell type, largely distinct from that in pain- | | | | |
| 30 | related traits, and shows BLA microglia are a key cell type. | | | | |

31 Introduction

32 Chronic pain affects roughly one fifth of adults in the United States ^{1,2}, and chronic pain 33 conditions (including low back pain and headache disorders) rank in the global top 10 non-34 infectious diseases contributing to disability adjusted life years ³. Chronic pain is defined as pain 35 lasting at least three months ^{4,5}. It is associated with a wide range of physical conditions and it 36 may follow surgery, injury or physical trauma ^{6,7}. Mechanisms of chronic pain development are 37 not fully understood, and for many individuals treatment is not effective, particularly long term ^{8–} ¹⁰.

39

40 Understanding the etiopathology of chronic pain requires that researchers investigate and compare the roles of predisposition to pain development, and effects stemming from experience 41 of pain. Studies of predisposition including large genome-wide association studies have 42 uncovered hundreds of trait-associated variants and genes ^{11,12}, and have suggested various 43 Central Nervous System (CNS) pathways to be important in chronic pain ¹³. However, these 44 45 findings (as with GWAS findings more broadly) have yet to be translated into full mechanistic 46 understanding of disease development, or into actionable treatment. One step toward addressing this knowledge gap is through analysis at the gene expression and transcriptomic level, 47 48 intermediate steps between genotype (GWAS findings) and phenotype (chronic pain). We and others have applied transcriptomic imputation approaches to translate GWAS findings into gene-49 tissue associations ^{14,15}, identifying brain regions with a putative role in chronic pain including 50 hippocampus, cerebellum, amygdala and frontal cortex among others. However, we do not yet 51 52 know which brain regions and cell types are primarily involved with chronic pain development. Rodents studies have identified >700 differentially expressed genes in brain and spinal cord, 53 54 associated with a range of phenotypes including chronic pain, post-surgical pain, neuropathic pain, and spinal injury ^{16–20}. 55

56

57 Meanwhile, human gene expression studies have focused on identifying genes associated with 58 specific chronic pain conditions, including fibromyalgia ²¹, osteoarthritis ²², migraine ²³, sickle 59 cell disease ²⁴, endometriosis ²⁵, and others ^{26–31}. However, sample sizes tend to be small, and 60 typically do not include brain tissue. Here, we present the largest study of differentially 61 expressed genes of brain tissue in chronic pain to date. We assess gene expression in post-

62 mortem brain tissues from 304 human donors, from four brain regions previously implicated in 63 pain processing and chronic pain (basal and medial amygdala, prefrontal and anterior cingulate 64 cortex), with detailed phenotype data. We ask whether chronic pain has region- and cell-type specific transcriptomic signatures in the human brain. Defining chronic pain is complex, and it is 65 vital to differentiate pain-associated transcriptomic signal from genes associated with 66 67 predisposition, specific pain-causing conditions (such as migraine), or genes with expression changes resulting from use of pain-alleviating medications (such as opioids). Using donor 68 phenotype and genotype data, we determine whether the transcriptomic signatures identified in 69 70 our analyses arise from predisposition to chronic pain, experience of pain itself, or due to 71 treatments or medications taken to alleviate pain (e.g., fentanyl, oxymorphone).

72

73 Methods

74 **Postmortem brain dataset description**

75 We obtained data for 304 postmortem human brains, donated at time of autopsy through US

76 medical examiner's offices, from the Veteran's Association (VA) National PTSD Brain Bank and

77 Traumatic Stress Brain Research group (**Table 1**). Retrospective clinical diagnostic review of

toxicology and next-of-kin interviews were performed in this previous study, and a wide range of

relinical, anthropometric, psychiatric and life history information, including on trauma history,

80 drug use, and presence of chronic pain, was collected. 115 total donors were female, 189 were

81 male, with a mean age of death of 46.75 years.

82

83 Bulk tissue was sampled from four regions of each brain; the dorsolateral anterior cingulate

84 cortex (dACC), dorsolateral prefrontal cortex (DLPFC), basolateral amygdala (BLA), and medial

85 amygdala (MeA), totaling 1216 samples. Collection of brain tissue samples postmortem,

86 genotyping, and producing gene expression data for this cohort is described in detail

elsewhere^{32,33}.

88

89 Chronic pain phenotype

90 Chronic pain in this dataset was encoded as present/absent (1/0) by researchers associated with

91 the original data collection, and may include a wide range of chronic pain conditions, locations

92 of chronic pain on the body, and varying severity. Chronic pain presence/ absence was derived

- 93 from multiple data sources including health records and next of kin interview during
- 94 retrospective clinical diagnostic review. Migraine, fentanyl lifetime use, and oxymorphone
- 95 lifetime use were determined using the same approach.
- 96

97 Imputation of cell-type level gene expression data from bulk tissue

98 To obtain imputed cell type level gene expression, we carried out cell type deconvolution and

99 subsequent estimation of cell type level gene expression. Since choice of reference panel impacts

- 100 cell type imputation accuracy ³⁴, we used two reference panels. We imputed both cortical bulk
- 101 tissues (DLPFC, dACC) with PsychENCODE reference cell types ^{35–37}, and both amygdala bulk
- tissues (BLA, MeA), using an amygdala specific reference panel ³⁸ (see Supplement). Six cell
- 103 types were available in both reference datasets (endothelial cells, microglia, inhibitory neurons,
- 104 excitatory neurons, oligodendrocytes and astrocytes) (see also Supplement).
- 105

106 Imputation was carried out in the same way across all tissues. First, using the bulk RNA-seq raw

107 counts, we constructed a matrix of transcripts, using CIBERSORTx ³⁹ and the appropriate

108 reference panel (cortex or amygdala) to estimate cell type proportions for bulk tissue regions.

109 bMind ⁴⁰ was used to impute cell type-specific gene expression for a total of six cell types in

- 110 each region (astrocytes, endothelial cells, excitatory neurons, inhibitory neurons, microglia, and
- 111 oligodendrocytes).
- 112

113 Finding differentially expressed genes using bulk tissue and cell type level expression data

114 We calculated surrogate variables (SVs) using bulk tissue gene expression data and preserving

for chronic pain, in order to capture sources of variability not directly measured in the study ⁴¹

using R package sva ⁴². We then checked for significant correlation between these SVs and our

measured variables using Pearson correlation tests. We next removed variables with more than

118 half of samples showing missing data, and then retained variables that were not correlated with at

- 119 least one SV (representing variables that were not fully captured by SVs). We then checked for
- 120 collinearity amongst these retained variables, removing variables and re-checking correlations in
- 121 a stepwise manner until a set of non-correlated (non-collinear) variables remained. These
- 122 uncorrelated-with-SVs, non-collinear variables were included as covariates alongside our SVs
- and chronic pain phenotype in a linear regression model to find differentially expressed genes in

124 chronic pain (see Table S1 for regression model per bulk tissue/ cell type analysis). We applied

125 Bonferroni correction within-tissue (total 4 tissues) to our regression p value results. We then

126 repeated DEG analysis steps (SVA, SV correlation check, collinearity check, DEG regression

- 127 analysis) for cell type level gene expression data, applying Bonferroni correction within tissue
- 128 within cell type (total 24 sets) to our results.
- 129

130 We repeated DEG analyses for lifetime fentanyl use, lifetime oxymorphone use, and migraine in

both bulk tissue and cell type. We carried out correlation tests among all lifetime opioid use

132 variables – fentanyl was significantly (p < 0.05, Pearson correlation test) correlated with most

133 other lifetime opioid use variables, except oxymorphone. Therefore, we chose fentanyl and

134 oxymorphone for DEG analyses, in order to investigate whether any chronic pain DEGs we

- 135 found reflected opioid treatment or use as a result of chronic pain.
- 136

137 Multiple Test Corrections

Unless stated otherwise, multiple test correction was carried out in each DEG analysis using a
Bonferroni correction for the number of genes tested. For bulk tissue analyses we applied
Bonferroni correction within-tissue, and for cell type analyses we applied Bonferroni multiple

141 testing correction within-tissue within cell type. We also apply a secondary experiment-wise

- 142 multiple test correction (see Supplement).
- 143

144 Pathway analyses of chronic pain DEGs using FUMA

145 We carried out gene-set enrichment tests within FUMA 43 using significant genes (P_{Bonferroni} <

146 0.05). We required at least 10 unique significant genes for inclusion in this analysis. Taking

147 DEGs from cell-type analyses in each tissue (total N=24 initial lists of significant genes), we

included gene lists containing more than ten unique genes. We used as background 17,550 genes

that were included in each of our DEG analyses per cell type, available in FUMA, and assigned

an Ensembl gene ID.

151

152 Comparing cell type DEGs and DAM/ARM and McGill Transcriptomic Pain Signatures

153 data

154 We next compiled a list of differentially expressed genes from the 'transcriptomics pain 155 signatures database' (TSPdb) maintained by the human pain genetics lab at McGill University ⁴⁴, 156 where data is available for human whole blood, synovial fluid, and cartilage transcriptomics experiments. We retained genes from human experiments in whole blood (the majority of the 157 158 human experiments in this database 1,260,387 (76% of experiments)), where the contrast 159 investigated was 'pain vs no pain', where sequencing was through high throughput and not 160 microarray, and where experiments had both males and females included. This resulted in a list of 203,984 experimental results comprised of 23,499 unique genes, 15,968 of which are also 161 tested in each of our cell type DEG analyses. We carried out a series of Fisher's exact tests for 162 163 enrichment of each list of chronic pain genes per cell type in this McGill database list, with the list of 15,968 shared genes as background. Note that it was not possible to directly test for DEG 164 165 enrichment (i.e., identical gene-tissue results) as opposed to enrichment for genes implicated in 166 DEGs (regardless of tissue), as the only human tissues available in the McGill database are nonbrain. 167

168

169 We then compiled a list of genes from the same database from experiments on mice (Mus musculus) and in brain and nervous tissues (Medical Subject Headings (MeSH) beginning 170 171 'A08..') (2,940,318 experiments). We then again included results where contrast investigated 172 was pain vs no pain, experiments used high throughput sequencing, and including both males 173 and females (206,827 experiments). The final database subset contained results for four tissues: 174 microglia (A08.637.400), brain stem (A08.186.211.132), spinal ganglia (A08.800.350.340), and 175 sciatic nerve (A08.800.800.720.450.760). We carried out a series of Fisher's exact tests for 176 enrichment of each list of chronic pain genes per cell type in each set of database results per 177 tissue.

178

We also compared our chronic pain microglia DEGs to disease-associated microglia (DAM) and activation response microglia (ARM) genes, using gene lists from publicly available information on DAMs and ARMs from two studies ^{45,46} compiled by Thrupp et al ⁴⁷ (Thrupp et al Table S1 'Genesets previous studies') (360 genes, of which 349 were also tested in our analyses). We did not carry out formal enrichment tests as it was not possible to discern the total number of genes shared as background between our analyses and the Thrupp et al gene list experiments.

185

186 Polygenic risk score analyses

187 We carried out analyses to uncover DEGs associated with polygenic risk of (proxying

188 predisposition to) chronic pain, using GWAS summary statistics for multisite chronic pain

189 (MCP) ⁴⁸.

190

191 First, using PLINK 1.9 and 2.0⁴⁹ we carried out recommended quality control (QC) procedure

192 for PRSice2 PRS analyses ⁵⁰. We removed duplicate and ambiguous (palindromic) SNPs from

193 our GWAS summary statistics, as well as SNPs with a low minor allele frequency (MAF < 0.01)

194 and low imputation quality (< 0.8).

195

196 Next, we carried out QC steps for genotype data associated with the postmortem brain dataset. 197 We excluded SNPs with MAF < 0.01, duplicate SNPs, SNPs with missing genotype call rates >0.01, and SNPs not in Hardy-Weinberg equilibrium ($p < 1x10^{-6}$). We also removed samples with 198 199 missing call rates greater than 0.01. Next, we LD-pruned SNPs in order to obtain a set of SNPs 200 in linkage equilibrium, using window size 200 bp, step size 25 bp, and a correlation threshold of 0.25 and PLINK –indep-pairwise. Then, we calculated sample heterozygosity using PLINK 2.0 – 201 202 het function, and excluded samples with values greater than 3 SDs from the mean sample 203 heterozygosity value. We then used PLINK 1.9 -check-sex function to flag samples where 204 genetic sex did not match reported sex, which were then removed. We filtered for genetic relatedness using PLINK 1.9 –rel-cutoff at a threshold of $\pi > 0.125$ (3rd degree relatives). We 205 206 performed PCA analysis using PLINK pca and the QC'd genotype data to obtain the first 20 genetic principal components for inclusion in the PRS calculation as covariates, to account for 207 208 population structure (particularly differing genetic ancestry between source GWAS cohort and 209 postmortem brain tissue donors).

210

211 We then used PRSice2 to calculate MCP-PRS for these N=250 post-QC postmortem brain cohort

212 participants. PRSice2 runs multiple PRS analyses at varying GWAS p value thresholds for

213 inclusion, returning a best-fit PRS (measured by PRS-trait regression R2 value). All SNPs

214 passing QC and associated with MCP were included in the PRS calculation. DEG analyses were

- then carried out as previously described using cell type level expression data, with the trait of
- 216 interest being MCP-PRS value for each donor rather than chronic pain.

218 Results

219 Chronic pain impacts the brain transcriptome in a region- and cell-type specific manner

220 In order to identify genes associated with chronic pain in cortical (dACC, DLPFC) and amygdala

221 (medial and basolateral) brain regions, we performed a differential expression analysis

comparing bulk tissue from individuals with and without histories of chronic pain. Two genes

223 were significantly downregulated in the dACC in individuals with chronic pain compared to

224 controls (Figure 1A), B4GALT2 (p=1.45x10⁻⁶, β = -0.936), and VEGFB (p=1.2x10⁻⁷, β =-


- **225** 0.945).
- 226

227 Since bulk tissue gene expression likely represents a combination of signal across cell types 228 sampled in each region, we repeated DEG analyses for each brain region using deconvoluted, 229 imputed cell type level expression data, across six cell types (Figure 1B; astrocytes, endothelial cells, excitatory neurons, inhibitory neurons, microglia, and oligodendrocytes). 2093 unique 230 231 genes were significantly associated with chronic pain in these imputed cell types, with the 232 majority of associations (1810/2326) in BLA microglia of the (Figure 1C, Figure S1). Given the 233 relatively small proportions of microglia in these brain regions, these associations represent a significant enrichment over what might be expected by chance $(p_{binomial} < 1x10^{-50})$. There was 234 235 also a significant enrichment of associations in medial amygdala endothelial cells (N DEGs = 254, $p_{binomial} = 1.3 \times 10^{-42}$). Findings in amygdala region oligodendrocyte progenitor cells (OPCs) 236 237 are presented in the Supplement (Table S2).

238

Chronic pain associated genes are enriched in hypoxia response, ribosome component, and immunity and infection-related pathways

We explored potential functional impact of chronic pain DEGs through gene set enrichment analyses, including all cell type DEG results with a sufficient number of unique significant genes; dACC microglia, dACC oligodendrocytes, BLA microglia, MeA microglia, MeA astrocytes, MeA endothelial, and MeA oligodendrocytes. Chronic pain associated genes in across these tissues and cell types were enriched for a total of 140 pathway enrichments comprising 101 unique pathways ($p_{Bonferroni} = 1.53 \times 10^{-6}$, adjusting across cell and tissue types, **Table S3**, **Supplement**).



249 250

Figure 1: Chronic pain DEGs are found in the dACC and in microglia of the basolateral amygdala in bulk and cell-type-level analyses.

253 1A: Bulk tissue chronic pain DEGs. Purple: significantly (P_{Bonferroni} < 0.05) downregulated, dotted line = DEG 254 regression p value significance threshold for that bulk region. FC = fold change. 1B: Imputed cell type proportions 255 vary across bulk regions - note neurons only present in reference data for cortex (Psychencode) and oligodendrocyte 256 progenitor cells (OPCs) only present in amygdala reference data (Yu et al), OPCs and Neurons both marked 'Other' 257 in this figure panel. FC = fold change. 1C: Chronic pain cell type DEGs in microglia per region. Purple = 258 significantly ($P_{Bonferroni} < 0.05$) downregulated, orange = significantly ($P_{Bonferroni} < 0.05$) upregulated, dotted line = p 259 value significance threshold. For legibility only the top 15 DEGs are labeled in cell type results panel. FC = fold260 change. InN = inhibitory neuron, ExN = excitatory neuron. 261

262

263 Significant enrichment of chronic pain genes in transcriptomic experiment results for

264 mouse CNS but not human whole blood

265 Chronic pain genes differentially expressed in the MeA microglia were significantly (Fisher's p =

266 0.01) enriched for mouse spinal ganglia genes from the McGill TSPdb (**Table 2**). Chronic pain

267 genes DE in the MeA astrocytes, and in dACC microglia and endothelial cells were also

significantly enriched for mouse microglia pain genes. There was no significant enrichment of

- 269 mouse sciatic nerve or mouse brain stem genes in our chronic pain DEG findings.
- 270

271 Sixty-seven genes identified as significantly DE in microglia were also up/down-regulated in

272 DAMs and/or ARMs (Table 3). Of these, 13 show concordant direction of effect across chronic

pain, DAMs, and ARMs, 21 show concordant effect across chronic pain and DAMs, and 17

across chronic pain and ARMs. None of our chronic pain genes were enriched for pain results

from human whole blood (Fisher's p > 0.05).

276

277 Chronic pain and polygenic risk for Multisite Chronic Pain are associated with differential 278 expression in unique sets of genes

To assess whether chronic pain DEGs represent predisposition to chronic pain, or are associated
with downstream impacts of pain on brain gene expression, we sought to identify DEGs
associated with polygenic risk for multisite chronic pain (MCP) at the cell type level. We found

282 21 DEGs significantly associated with MCP-PRS (**Table 4**), none of which were identified as

283 chronic pain DEGs in our previous analyses.

284

285 Migraine and chronic pain DEGs significantly overlap in medial amygdala endothelial cells

286 In order to distinguish genes associated with chronic pain from genes associated with specific

chronic pain conditions, we tested for migraine DEGs in bulk- and imputed cell type data.

Although no genes were significantly associated with migraine in bulk tissue, 942 DEGs were

associated at the cell-type level, with an over-representation in microglia (754/942 DEGs,

290 $p_{binomial} < 2x10^{-16}$; albeit in the MeA rather than BLA), in dACC oligodendrocytes (52/942,

- binomial p = 0.027), and in MeA endothelial cells (117/942, binomial $p = 3.3 \times 10^{-25}$). Twelve
- 292 DEGs were associated with both migraine and chronic pain (Table S4), representing a significant
- overlap overall (Fisher's p = 0.004), with this enrichment being driven solely by DEGs in MeA

endothelial cells (hypergeometric p = 0.02, Table S5).

296 Chronic pain associations are not driven by opioid use

- 297 Chronic pain gene associations may also be confounded by long-term use of medications taken
- to address pain. To test this, we identified DEGs associated with lifetime fentanyl (fentanyl
- 299 DEGs) and oxymorphone use (oxymorphone DEGs), and compared both single-gene and
- 300 genome-wide associations to our chronic pain signatures.
- 301
- 302 At the bulk level, we identified one gene significantly downregulated in individuals with a
- 303 lifetime history of oxymorphone use in MeA (GPR158.AS1; p=1.17x10⁻⁰⁶). This DEG was not a
- 304 chronic pain DEG in bulk tissue. At the cell-type level, we identified 744 significant
- 305 oxymorphone DEGs, of which 13 were also previously associated with chronic pain (Table S6,
- 306 Figure 2). Oxymorphone DEGs significantly overlapped with chronic pain DEGs
- 307 (hypergeometric p < 0.05) in both BLA and MeA endothelial cells and microglia (Table S7).
- 308 No genes were significantly associated with fentanyl use in bulk tissue. Cell-type specific
- analyses identified 17 significant fentanyl DEGs (Table S8); however, none of these DEGs
- 310 overlapped with chronic pain.
- 311




Figure 2: Cell type DEG overlap across all traits (lifetime oxymorphone use, lifetime

fentanyl use, multisite chronic pain PRS, chronic pain, and migraine) tends to be low. PRS

315 – polygenic risk score (MCP-PRS).

316

317 Discussion

318 Understanding the etiopathology of chronic pain requires careful dissection of chronic pain risk, 319 experience, and treatment. Here, we characterize the impact of each of these distinct factors on brain gene expression; we show that chronic pain primarily impacts gene expression in amygdala 320 microglia, and that this transcriptomic signature is for the most part distinct from the signatures 321 322 of pain predisposition, or the impacts of taking pain-alleviating medications. Our study is the largest to examine the impact of chronic pain across brain regions through differential expression 323 324 analysis of brain tissue. Strengths of our study include large sample size, with 304 donors and 4 brain regions (all previously implicated in chronic pain) sampled per donor. In addition, a large 325 amount of phenotypic data for each donor is available (160+ variables on lifestyle, trauma, 326 327 psychiatric and medical diagnoses, and lifetime substance and medication use), allowing us to 328 thoroughly account for sources of variance in gene expression that are not due to chronic pain or other trait-of-interest status. We use two separate region matched reference datasets for cortex 329 330 and amygdala to study cell type level gene expression imputation. In addition, unusually for 331 chronic pain studies, our sample is almost perfectly balanced in terms of reported sex in donors 332 with chronic pain.

333

334 Microglia represent a key cell type in chronic pain

We leverage advances in cell-type imputation, coupled with large, well-powered cell imputation reference panels to expand our study beyond region specificity, to look at cell-type specificity. We find the majority of our associations in microglia. In addition, we find our chronic pain genes to be enriched in mouse results in CNS and microglia from the pain transcriptomic signatures database, and to show partial overlap with genes associated with DAMs (disease-activated microglia) and ARMs (activated response microglia), reactive microglia phenotypes associated with neurodegenerative disease ^{46,51,52}.

343 In the context of chronic pain, microglia have previously been implicated in imaging studies of 344 low back pain patients ⁵³, in the transition from acute to chronic pain in rodent models of spinal 345 nerve transection ⁵⁴, in chronic visceral pain ⁵⁵, and in general neuroplasticity related to chronic pain ⁵⁶. Specifically in BLA microglia, studies in rodents found inhibition of these cells increased 346 347 anti-nociceptive effects of opioid drugs ⁵⁷, and reduced pain-induced depressive behaviour in a bone cancer pain model ⁵⁸. Our results indicate that BLA microglia play an important part in 348 human chronic pain, that significant overlap is present between human and mouse chronic pain 349 350 DEGs in microglia, and that the transcriptomic changes in microglia in chronic pain do not 351 exactly match many of those seen in DAMs/ARMs.

352

353 Impact of pain-related factors and conditions on gene expression in the brain

Importantly, our study compares and contrasts different factors involved in pain. There may be key differences in transcriptional changes that occur as a result of living with chronic pain, with predisposition to developing chronic pain, and with indirect results of chronic pain such as potential opioid use. Furthermore, distinct genes may be differentially expressed in chronic pain

358 compared to more specific chronic pain conditions such as migraine.

359

360 Genetic predisposition to chronic pain is transcriptomically distinct from experience of

361 chronic pain

We found distinct sets of genes associated with experience of chronic pain (i.e., observed in brain expression) compared to genetic predisposition to chronic pain (which we measure through polygenic risk for Multisite Chronic Pain). We note that although our sample size (304 donors) is low for polygenic risk score analyses, this sample size paired with the large base GWAS (N > 380, 000 participants), is considered acceptably powered ⁵⁹.

367

There are no DEGs shared between polygenic risk for multisite chronic pain and chronic pain as a trait. In contrast to chronic pain DEGs, DEGs for polygenic risk of multisite chronic pain were found primarily in dACC oligodendrocytes (19/21 DEGs), in contrast to BLA microglia which appear to play a role in established chronic pain. Previous studies have shown oligodendrocytes may contribute to chronic pain development ⁶⁰, in addition to evidence in rodent models that oligodendrocyte ablation can induce central pain without immune / other glial cell input ⁶¹.

| 5/4 | 3 | 7 | 4 |
|-----|---|---|---|
|-----|---|---|---|

| 374 | |
|-----|--|
| 375 | Genes differentially expressed with increasing polygenic risk of MCP included genes with |
| 376 | previous evidence of involvement in pain and cardiac phenotypes, including Fam13b (associated |
| 377 | with mouse cardiac phenotypes, 82), TRAF5 (vascular inflammation and atherosclerosis, 83), |
| 378 | and FAM184B (heart disease and hip pain ⁶⁴). These associations are in line with established |
| 379 | links between chronic pain and heart conditions ⁶⁵ , including in our own previous work showing |
| 380 | pain gene associations with cardiac dysrhythmias in a large EHR ¹⁴ . Other MCP-PRS associated |
| 381 | genes have previous evidence of association with pain phenotypes, including DOCK3 66, |
| 382 | LAMB1 ⁶⁷ , DUSP4 ⁶⁸ , and C1QTNF7 ⁶⁹ . Several genes were associated with nerve injury and |
| 383 | neuropathies, including NCOA5 ⁷⁰ , EPHA5 ⁷¹ , FZD4 ⁷² , and MRPL48 ⁷³ , and NFKBID ⁷⁴ . |
| 384 | |
| 385 | Opioid and chronic pain DEG overlap is small and concentrated in the amygdala |
| 386 | At the cell level, none of the chronic pain DEGs overlapped with those associated with lifetime |
| 387 | fentanyl use, and 13 DEGs overlapped between chronic pain and lifetime oxymorphone use. |
| 388 | These 13 overlapping DEGs represented significant general enrichment of chronic pain DEGs |
| 389 | within oxymorphone DEGs (Fisher's $p = 0.0001$), but this was driven by four specific cell types |
| 390 | (each showing hypergeometric $p < 0.05$); BLA microglia, BLA endothelial cells, MeA microglia |
| 391 | and MeA endothelial cells. |
| 392 | |
| 393 | Overlapping DEGs in oxymorphone and chronic pain had concordant direction of effect (i.e., |
| 394 | genes significantly downregulated in chronic pain tend to also be downregulated in lifetime |
| 395 | oxymorphone use). Although we did not explicitly examine opioid induced hyperalgesia (OIH), |
| 396 | these results suggest transcriptomic changes associated with both increased pain and |
| 207 | avymorphone use are present in these call types of the amyodale notentially representing |

397 oxymorphone use are present in these cell types of the amygdala, potentially representing

relevant genes and cell types in OIH.

399

400 Genes differentially expressed in both oxymorphone and chronic pain (13 DEGs) included those

401 implicated in TNF response and previously linked to Lyme disease (YBX3, ^{75,76}), encoding

402 cytokines (CCL2, ⁷⁷), Raine syndrome and bone mineralization (FAM20C, ^{78,79}), autocrine

403 signaling and lipid storage (HILPDA, ⁸⁰), connective tissue biogenesis (LOXL2, ⁸¹),

404 neurogenesis (RASF10, ⁸²), and Alzheimer disease, Parkinson disease, schizophrenia, and PTSD

405 (SERPINA3, ^{83–86}). YBX3 gene expression in the brain has also been previously linked to
 406 PTSD⁸⁷.

407

408 Migraine and chronic pain DEG overlap is small and driven by amygdala endothelial cells

409 Pathophysiology of migraine is not completely understood ^{88,89}, and as with all conditions where

410 chronic pain is a main symptom, there may be distinct mechanisms underlying condition-specific

411 processes and potential tissue damage vs a general chronic pain phenotype. We explored this

through comparing genes differentially expressed in migraine and in chronic pain, finding small

- 413 (12 DEGs) but significant overlap driven by endothelial cells of the medial amygdala.
- 414

415 Endothelial cells interface with vasculature, and endothelial dysfunction has been previously

416 implicated in migraine, although it is not fully established whether this dysfunction is a cause or

417 consequence of migraine ⁹⁰. Significant overlap in chronic pain and migraine DEGs in medial

418 amygdala endothelial cells could therefore mean transcriptomic changes at endothelial cells and

419 migraine-related pain are specifically linked (as opposed to non-pain related migraine symptoms,

- 420 and non-migraine/ general chronic pain).
- 421

422 In addition, VEGF, encoded by VEGFA, is a 'protective angiogenic factor' in migraine ⁹⁰.

423 VEGFB (in contrast to VEGFA) is 'dispensable' in new blood vessel growth in normal tissue but

424 seems to play a more essential role in neurodegenerative diseases and stroke (protecting various

425 vasculature during disease progression) ⁹¹. VEGF has also been implicated in rodent and human

426 studies of neuroplasticity, stress response, and antidepressant action ^{92–96}. Our results showed

427 VEGFB was downregulated in bulk dACC tissue in chronic pain, indicating VEGFB may

represent a protective angiogenic factor outside of migraine, and in a general chronic paincontext.

430

431 Limitations

432 There are some key limitations of our study that should be borne in mind when interpreting our

433 results. The chronic pain phenotype is extremely broad and dichotomized. Opioid use

434 phenotypes were similarly broad, and lifetime use did not delineate between prescribed/ non-

435 prescribed, and current or past use. When comparing lifetime fentanyl use and lifetime

oxymorphone use, 'case' numbers are higher for fentanyl, but far fewer DEGs are found – there
are also no overlapping DEGs between the two traits. This may reflect different clinical uses of
these drugs, with fentanyl as a more discrete rather than chronic exposure, making effects on
gene expression more difficult to capture post-mortem and potentially long after a brief
exposure.
Another limitation is lack of human brain tissue experiment data available in the McGill TSPdb
for direct comparisons with our results, although we explored enrichment in human whole blood

443 444

445 Conclusions

and mouse brain and nervous system results.

Our results suggest that chronic pain impacts gene expression in a heterogeneous way within 446 447 brain regions depending on cell type, and signal from cell type expression changes may be hidden in bulk tissue analyses due to heterogeneous cell type populations. We highlight brain 448 449 region and cell type specific genes differentially expressed in chronic pain. In particular, our results suggest BLA microglia are a key cell type in chronic pain, and that pain related 450 451 transcriptomic changes are distinct from those seen in neurodegenerative disease and general 452 neuroinflammation. Our microglia findings were also enriched for genes differentially expressed 453 in mouse microglia and spinal ganglia samples, but not in human whole blood, again emphasizing region and cell specificity and suggesting a degree of cross-species conservation of 454 455 certain chronic pain associated transcriptomic changes. Pathways enriched for genes 456 significantly differentially expressed in these cells in chronic pain include those involved in 457 immune processes and hypoxia response. Migraine, opioid use, genetic predisposition to chronic 458 pain, and chronic pain are all largely distinct at the transcriptome level. Points of overlap, though 459 overall consisting of a small number of genes, can inform potential mechanisms underlying 460 shared characteristics between traits. Differences at the transcriptome level between 461 predisposition to chronic pain and chronic pain can be potentially used to inform tailoring of 462 treatment to stage in chronic pain development.

- 463
- 464
- 465
- 466

478 References

- 1. Rikard, S. M., Strahan, A. E., Schmit, K. M. & Guy, G. P. Chronic Pain Among Adults -
- 480 United States, 2019-2021. *MMWR Morb. Mortal. Wkly. Rep.* **72**, 379–385 (2023).
- 481 2. Yong, R. J., Mullins, P. M. & Bhattacharyya, N. Prevalence of chronic pain among adults in
- 482 the United States. *PAIN* **163**, e328 (2022).
- 483 3. Vos, T. *et al.* Global burden of 369 diseases and injuries in 204 countries and territories,
- 484 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*485 **396**, 1204–1222 (2020).
- 486 4. Mills, S. E. E., Nicolson, K. P. & Smith, B. H. Chronic pain: a review of its epidemiology
- 487 and associated factors in population-based studies. *Br. J. Anaesth.* **123**, e273–e283 (2019).
- 488 5. Terminology | International Association for the Study of Pain. *International Association for*489 *the Study of Pain (IASP)* https://www.iasp-pain.org/resources/terminology/.
- 490 6. Apkarian, A. V., Baliki, M. N. & Geha, P. Y. Towards a theory of chronic pain. *Prog.*491 *Neurobiol.* 87, 81–97 (2009).
- 492 7. Dueñas, M., Ojeda, B., Salazar, A., Mico, J. A. & Failde, I. A review of chronic pain impact
- 493 on patients, their social environment and the health care system. J. Pain Res. 9, 457–467
- 494 (2016).
- 495 8. Jonas, W. B. *et al.* Are Invasive Procedures Effective for Chronic Pain? A Systematic
 496 Review. *Pain Med. Off. J. Am. Acad. Pain Med.* 20, 1281–1293 (2019).
- 497 9. Busse, J. W. *et al.* Opioids for Chronic Noncancer Pain: A Systematic Review and Meta498 analysis. *JAMA* 320, 2448–2460 (2018).
- 499 10. Chou, R. *et al.* Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review
- 500 for an American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 166,
- 501 480–492 (2017).

| 502 | 11. Hébert, H. L., Pascal, M. M. V., Smith, B. H., Wynick, D. & Bennett, D. L. H. Big data, big |
|-----|---|
| 503 | consortia, and pain: UK Biobank, PAINSTORM, and DOLORisk. PAIN Rep. 8, e1086 |
| 504 | (2023). |

- 12. Diatchenko, L., Parisien, M., Jahangiri Esfahani, S. & Mogil, J. S. Omics approaches to
- discover pathophysiological pathways contributing to human pain. *Pain* **163**, S69–S78
- 507 (2022).
- 508 13. Farrell, S. F. *et al.* Genetic basis to structural grey matter associations with chronic pain.
 509 *Brain J. Neurol.* 144, 3611–3622 (2021).
- 510 14. Johnston, K. J. A., Cote, A. C., Hicks, E., Johnson, J. & Huckins, L. M. Genetically
- 511 Regulated Gene Expression in the Brain Associated With Chronic Pain: Relationships With
- 512 Clinical Traits and Potential for Drug Repurposing. *Biol. Psychiatry* (2023)
- 513 doi:10.1016/j.biopsych.2023.08.023.
- 514 15. Nisbet, L. N. & McIntosh, A. M. The Potential of Genomics and Electronic Health Records
- to Invigorate Drug Development. *Biol. Psychiatry* **95**, 715–717 (2024).
- 516 16. Bangash, M. A. et al. Distinct transcriptional responses of mouse sensory neurons in models
- 517 of human chronic pain conditions. *Wellcome Open Res.* **3**, 78 (2018).
- 518 17. Pokhilko, A., Nash, A. & Cader, M. Z. Common transcriptional signatures of neuropathic
- 519 pain. *Pain* **161**, 1542–1554 (2020).
- 520 18. Xu, R. *et al.* Genome-Wide Expression Profiling by RNA-Sequencing in Spinal Cord Dorsal
- 521 Horn of a Rat Chronic Postsurgical Pain Model to Explore Potential Mechanisms Involved in
- 522 Chronic Pain. J. Pain Res. 15, 985–1001 (2022).
- 523 19. Zhang, G. & Yang, P. Bioinformatics Genes and Pathway Analysis for Chronic Neuropathic
- 524 Pain after Spinal Cord Injury. *BioMed Res. Int.* 2017, 6423021 (2017).

| 525 | 20. | Bai, J., Geng, B., Wang, X., Wang, S. & Xia, Y. Analysis of Potential Hub Genes for |
|-----|-----|--|
| 526 | | Neuropathic Pain Based on Differential Expression in Rat Models. Pain Res. Manag. 2022, |
| 527 | | 6571987 (2022). |
| 528 | 21. | Lukkahatai, N., Walitt, B., Espina, A., Wang, D. & Saligan, L. N. Comparing Genomic |
| 529 | | Profiles of Women With and Without Fibromyalgia. Biol. Res. Nurs. 17, 373–383 (2015). |
| 530 | 22. | Chu, ZC. et al. The identification of hub-methylated differentially expressed genes in |
| 531 | | osteoarthritis patients is based on epigenomic and transcriptomic data. Front. Med. 10, |
| 532 | | 1219830 (2023). |
| 533 | 23. | Kogelman, L. J. A. et al. Changes in the gene expression profile during spontaneous |
| 534 | | migraine attacks. Sci. Rep. 11, 8294 (2021). |
| 535 | 24. | Mucalo, L. et al. Identification Of Hub Genes Associated With Acute Pain Episodes In |
| 536 | | Individuals With Sickle Cell Disease. J. Pain 24, 16–17 (2023). |
| 537 | 25. | Walker, E. R., McGrane, M., Aplin, J. D., Brison, D. R. & Ruane, P. T. A systematic review |
| 538 | | of transcriptomic studies of the human endometrium reveals inconsistently reported |
| 539 | | differentially expressed genes. Reprod. Fertil. 4, (2023). |
| 540 | 26. | Hautakangas, H. et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk |
| 541 | | loci and subtype-specific risk alleles. Nat. Genet. 54, 152-160 (2022). |
| 542 | 27. | Yin, X. et al. Biological insights into systemic lupus erythematosus through an immune cell- |
| 543 | | specific transcriptome-wide association study. Ann. Rheum. Dis. 81, 1273-1280 (2022). |
| 544 | 28. | Doke, T. et al. Transcriptome-wide association analysis identifies DACH1 as a kidney |
| 545 | | disease risk gene that contributes to fibrosis. J. Clin. Invest. 131, (2021). |
| | | |
| | | |
| | | |

- 546 29. Díez-Obrero, V. et al. Transcriptome-Wide Association Study for Inflammatory Bowel
- 547 Disease Reveals Novel Candidate Susceptibility Genes in Specific Colon Subsites and Tissue
- 548 Categories. J. Crohns Colitis 16, 275–285 (2022).
- 549 30. Starobova, H., A, H. S. W., J. Lewis, R. & Vetter, I. Transcriptomics in pain research: insights
- from new and old technologies. *Mol. Omics* **14**, 389–404 (2018).
- 551 31. Hu, L., Yin, W., Ma, Y., Zhang, Q. & Xu, Q. Gene expression signature of human
- neuropathic pain identified through transcriptome analysis. *Front. Genet.* 14, (2023).
- 553 32. Seah, C. *et al.* Common genetic variation impacts stress response in the brain.
- 554 2023.12.27.573459 Preprint at https://doi.org/10.1101/2023.12.27.573459 (2023).
- 555 33. Jaffe, A. E. et al. Decoding Shared Versus Divergent Transcriptomic Signatures Across
- 556 Cortico-Amygdala Circuitry in PTSD and Depressive Disorders. *Am. J. Psychiatry* 179,
 557 673–686 (2022).
- 34. Sutton, G. J. *et al.* Comprehensive evaluation of deconvolution methods for human brain
 gene expression. *Nat. Commun.* 13, 1358 (2022).
- 560 35. Lake, B. B. *et al.* Integrative single-cell analysis of transcriptional and epigenetic states in
 561 the human adult brain. *Nat. Biotechnol.* 36, 70–80 (2018).
- 562 36. Darmanis, S. *et al.* A survey of human brain transcriptome diversity at the single cell level.
- 563 *Proc. Natl. Acad. Sci.* **112**, 7285–7290 (2015).
- 564 37. Lake, B. B. et al. Neuronal subtypes and diversity revealed by single-nucleus RNA
- sequencing of the human brain. *Science* **352**, 1586–1590 (2016).
- 566 38. Yu, B. *et al.* Molecular and cellular evolution of the amygdala across species analyzed by
- single-nucleus transcriptome profiling. *Cell Discov.* 9, 1–22 (2023).

- 39. Newman, A. M. *et al.* Determining cell type abundance and expression from bulk tissues
 with digital cytometry. *Nat. Biotechnol.* 37, 773–782 (2019).
- 570 40. Wang, J., Roeder, K. & Devlin, B. Bayesian estimation of cell type-specific gene expression
- with prior derived from single-cell data. *Genome Res.* **31**, 1807–1818 (2021).
- 572 41. Leek, J. T. & Storey, J. D. Capturing Heterogeneity in Gene Expression Studies by Surrogate
 573 Variable Analysis. *PLOS Genet.* 3, e161 (2007).
- 42. Leek JT, Johnson WE, Parker HS, Fertig EJ, Jaffe AE, Zhang Y, Storey JD, Torres LC. sva:
 Surrogate Variable Analysis. (2023).
- 43. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
- 578 44. Transcriptomics Pain Signatures Database. https://transcriptomicspainsignaturesdb.ca/.
- 579 45. Keren-Shaul, H. *et al.* A Unique Microglia Type Associated with Restricting Development of
- 580 Alzheimer's Disease. *Cell* **169**, 1276-1290.e17 (2017).
- 581 46. Sala Frigerio, C. et al. The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes
- 582 Modulate the Microglia Response to $A\beta$ Plaques. *Cell Rep.* **27**, 1293-1306.e6 (2019).
- 583 47. Thrupp, N. *et al.* Single-Nucleus RNA-Seq Is Not Suitable for Detection of Microglial
- 584
 Activation Genes in Humans. Cell Rep. 32, 108189 (2020).
- 585 48. Johnston, K. J. A. *et al.* Genome-wide association study of multisite chronic pain in UK
 586 Biobank. *PLOS Genet.* 15, e1008164 (2019).
- 49. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
 Linkage Analyses. *Am. J. Hum. Genet.* 81, 559 (2007).
- 589 50. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk
- 590 score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).

- 51. Wei, Y. & Li, X. Different phenotypes of microglia in animal models of Alzheimer disease. *Immun. Ageing* 19, 44 (2022).
- 593 52. Woodburn, S. C., Bollinger, J. L. & Wohleb, E. S. The semantics of microglia activation:
- neuroinflammation, homeostasis, and stress. J. Neuroinflammation 18, 258 (2021).
- 53. Loggia, M. L. *et al.* Evidence for brain glial activation in chronic pain patients. *Brain* 138,
 604–615 (2015).
- 54. Peng, J. *et al.* Microglia and monocytes synergistically promote the transition from acute to
 chronic pain after nerve injury. *Nat. Commun.* 7, 12029 (2016).
- 55. Long, J.-Y. et al. Spinal Microglia and Astrocytes: Two Key Players in Chronic Visceral Pain
- 600 Pathogenesis. *Neurochem. Res.* 47, 545–551 (2022).
- 56. Hiraga, S., Itokazu, T., Nishibe, M. & Yamashita, T. Neuroplasticity related to chronic pain
 and its modulation by microglia. *Inflamm. Regen.* 42, 15 (2022).
- 57. Kosarmadar, N., Ghasemzadeh, Z. & Rezayof, A. Inhibition of microglia in the basolateral
- amygdala enhanced morphine-induced antinociception: Possible role of GABAA receptors.
- 605 *Eur. J. Pharmacol.* **765**, 157–163 (2015).
- 58. Jiang, L. et al. Basolateral Amygdala Reactive Microglia May Contribute to Synaptic
- 607 Impairment and Depressive-Like Behavior in Mice with Bone Cancer Pain. *Neurochem. Res.*
- **608 47**, 3454–3463 (2022).
- 59. Choi, S. W., Mak, T. S. H. & O'Reilly, P. F. A guide to performing Polygenic Risk Score
 analyses. *Nat. Protoc.* 15, 2759–2772 (2020).
- 60. Malta, I., Moraes, T., Rodrigues, G., Franco, P. & Galdino, G. The role of oligodendrocytes
- 612 in chronic pain: cellular and molecular mechanisms. J. Physiol. Pharmacol. Off. J. Pol.
- 613 *Physiol. Soc.* **70**, (2019).

- 614 61. Gritsch, S. *et al.* Oligodendrocyte ablation triggers central pain independently of innate or
 615 adaptive immune responses in mice. *Nat. Commun.* 5, 5472 (2014).
- 616 62. Tchou, G. et al. Decreased FAM13B Expression Increases Atrial Fibrillation Susceptibility
- 617 by Regulating Sodium Current and Calcium Handling. *JACC Basic Transl. Sci.* 8, 1357–
- 618 1378 (2023).
- 619 63. Gissler, M. C., Stachon, P., Wolf, D. & Marchini, T. The Role of Tumor Necrosis Factor
- 620 Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis. *Front.*
- 621 *Cardiovasc. Med.* 9, (2022).
- 622 64. TWAS hub FAM184B. http://twas-hub.org/genes/FAM184B/.
- 65. Reynolds, C. A. & Minic, Z. Chronic Pain-Associated Cardiovascular Disease: The Role of
 Sympathetic Nerve Activity. *Int. J. Mol. Sci.* 24, 5378 (2023).
- 625 66. Ray, P. et al. Comparative transcriptome profiling of the human and mouse dorsal root
- ganglia: an RNA-seq-based resource for pain and sensory neuroscience research. *Pain* 159, 1325–1345 (2018).
- 628 67. Li, Z.-Z. *et al.* Extracellular matrix protein laminin β 1 regulates pain sensitivity and
- 629 anxiodepression-like behaviors in mice. J. Clin. Invest. 131, e146323.
- 630 68. Li, Z. & Chen, B. DUSP4 alleviates LPS-induced chondrocyte injury in knee osteoarthritis
- 631 via the MAPK signaling pathway. *Exp. Ther. Med.* **22**, 1401 (2021).
- 632 69. Goldmann, K. et al. Expression quantitative trait loci analysis in rheumatoid arthritis
- 633 identifies tissue specific variants associated with severity and outcome. *Ann. Rheum. Dis.*
- 634 (2023) doi:10.1136/ard-2023-224540.
- 635 70. Chan, A. C. Y. *et al.* Novel Autoantibodies in Idiopathic Small Fiber Neuropathy. *Ann.*
- 636 *Neurol.* **91**, 66–77 (2022).

- 637 71. Barquilla, A. & Pasquale, E. B. Eph Receptors and Ephrins: Therapeutic Opportunities.
- 638 *Annu. Rev. Pharmacol. Toxicol.* 55, 465–487 (2015).
- 639 72. Tang, Y. *et al.* Wnt Signaling Pathways: A Role in Pain Processing. *Neuromolecular Med.* 24,
 640 233–249 (2022).
- 641 73. Tilley, D. M. et al. Proteomic Modulation in the Dorsal Spinal Cord Following SCS therapy
- 642 in an in vivo Neuropathic Pain Model. *Neuromodulation J. Int. Neuromodulation Soc.* 24,
- 643 22–32 (2021).
- 644 74. Descalzi, G. *et al.* Neuropathic pain promotes adaptive changes in gene expression in brain
- 645 networks involved in stress and depression. *Sci. Signal.* **10**, eaaj1549 (2017).
- 646 75. Rouillard, A. D. *et al.* The harmonizome: a collection of processed datasets gathered to serve
 647 and mine knowledge about genes and proteins. *Database* 2016, baw100 (2016).
- 648 76. Goettner, G. et al. Improvement of Lyme Borreliosis Serodiagnosis by a Newly Developed
- 649 Recombinant Immunoglobulin G (IgG) and IgM Line Immunoblot Assay and Addition of

650 VIsE and DbpA Homologues. J. Clin. Microbiol. 43, 3602–3609 (2005).

- 651 77. Gschwandtner, M., Derler, R. & Midwood, K. S. More Than Just Attractive: How CCL2
- Influences Myeloid Cell Behavior Beyond Chemotaxis. *Front. Immunol.* **10**, 2759 (2019).
- 653 78. Liu, C. *et al.* FAM20C regulates osteoblast behaviors and intracellular signaling pathways in
 654 a cell-autonomous manner. *J. Cell. Physiol.* 233, 3476–3486 (2018).
- 79. Wang, X. *et al.* Expression of FAM20C in the Osteogenesis and Odontogenesis of Mouse. *J. Histochem. Cytochem.* 58, 957–967 (2010).
- 657 80. Deng, L., Wu, S. A., Qi, L. & Kersten, S. HILPDA is a lipotoxic marker in adipocytes that
- 658 mediates the autocrine negative feedback regulation of triglyceride hydrolysis by fatty acids
- and alleviates cellular lipotoxic stress. *Mol. Metab.* **75**, 101773 (2023).

- 660 81. Saux, C. J.-L. *et al.* The *LOXL2* Gene Encodes a New Lysyl Oxidase-like Protein and Is
- Expressed at High Levels in Reproductive Tissues*. J. Biol. Chem. 274, 12939–12944
 (1999).
- 663 82. Sherwood, V., Recino, A., Jeffries, A., Ward, A. & Chalmers, A. D. The N-terminal RASSF
- family: a new group of Ras-association-domaincontaining proteins, with emerging links to
 cancer formation. *Biochem. J.* 425, 303–311 (2009).
- 666 83. Sánchez-Navarro, A., González-Soria, I., Caldiño-Bohn, R. & Bobadilla, N. A. An
- 667 integrative view of serpins in health and disease: the contribution of SerpinA3. Am. J.
- 668 *Physiol. Cell Physiol.* **320**, C106–C118 (2021).
- 84. Zattoni, M. *et al.* Serpin Signatures in Prion and Alzheimer's Diseases. *Mol. Neurobiol.* 59,
 3778–3799 (2022).
- 671 85. Bhuvaneshwar, K. & Gusev, Y. Translational bioinformatics and data science for biomarker
- discovery in mental health: an analytical review. *Brief. Bioinform.* **25**, bbae098 (2024).
- 673 86. Su, Y. A. et al. Dysregulated Mitochondrial Genes and Networks with Drug Targets in
- 674 Postmortem Brain of Patients with Posttraumatic Stress Disorder (PTSD) Revealed by
- Human Mitochondria-Focused cDNA Microarrays. Int. J. Biol. Sci. 4, 223–235 (2008).
- 676 87. Girgenti, M. J. et al. Transcriptomic organization of the human brain in post-traumatic stress
- 677 disorder. *Nat. Neurosci.* **24**, 24–33 (2021).
- 678 88. Mungoven, T. J., Henderson, L. A. & Meylakh, N. Chronic Migraine Pathophysiology and
- 679 Treatment: A Review of Current Perspectives. *Front. Pain Res.* 2, (2021).
- 680 89. Ashina, M. Migraine. N. Engl. J. Med. 383, 1866–1876 (2020).

- 681 90. Paolucci, M., Altamura, C. & Vernieri, F. The Role of Endothelial Dysfunction in the
- 682 Pathophysiology and Cerebrovascular Effects of Migraine: A Narrative Review. J. Clin.
- 683 *Neurol. Seoul Korea* **17**, 164–175 (2021).
- 684 91. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B
- 685 targeting inhibits pathological angiogenesis | PNAS.
- 686 https://www.pnas.org/doi/full/10.1073/pnas.0813061106.
- 687 92. Deyama, S., Li, X. & Duman, R. S. Neuron-specific deletion of VEGF or its receptor Flk-1
- 688 occludes the antidepressant-like effects of desipramine and fluoxetine in mice.
- 689 *Neuropsychopharmacol. Rep.* **44**, 246–249 (2023).
- 690 93. Deyama, S., Li, X.-Y. & Duman, R. S. Neuron-specific deletion of VEGF or its receptor Flk-
- 691 1 impairs recognition memory. *Eur. Neuropsychopharmacol. J. Eur. Coll.*
- 692 *Neuropsychopharmacol.* **31**, 145–151 (2020).
- 693 94. Deyama, S., Bang, E., Kato, T., Li, X.-Y. & Duman, R. S. Neurotrophic and Antidepressant
- 694 Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor.
- 695 *Biol. Psychiatry* **86**, 143–152 (2019).
- 696 95. Deyama, S. *et al.* Role of neuronal VEGF signaling in the prefrontal cortex in the rapid
- 697 antidepressant effects of ketamine. Am. J. Psychiatry 176, 388–400 (2019).
- 698 96. Newton, S. S., Fournier, N. M. & Duman, R. S. Vascular growth factors in neuropsychiatry.
- 699 *Cell. Mol. Life Sci. CMLS* **70**, 1739–1752 (2013).

700

702 Acknowledgements

- 703 The authors acknowledge support by the National PTSD Brain Bank of the National Center for
- 704 PTSD (Department of Veterans Affairs). LMH acknowledges funding from NIMH
- 705 (R01MH124839, R01MH118278, R01MH125938, RM1MH132648, R01MH136149), NIEHS
- 706 (R01ES033630), and the Department of Defense (TP220451). JHK acknowledges support from
- the Clinical Neuroscience Division of the National Center for PTSD (Department of Veterans
- Affairs). CS acknowledges funding from NIH (F30MH132324).
- 709 The authors thank members of the Traumatic Stress Brain Research Group (Consortia Authors):
- 710 Victor E. Alvarez, MD, David Benedek, MD, Alicia Che, PhD, Dianne A. Cruz, MS, David A.
- 711 Davis, PhD, Matthew J. Girgenti, PhD, Ellen Hoffman, MD, PhD, Paul E. Holtzheimer, MD,
- 712 Bertrand R. Huber, MD, PhD, Alfred Kaye, MD, PhD, John H. Krystal, MD, Adam T. Labadorf,
- 713 PhD, Terence M. Keane, PhD, Mark W. Logue, PhD, Ann McKee, MD, Brian Marx, PhD, Mark
- 714 W. Miller, PhD, Crystal Noller, PhD, Janitza Montalvo-Ortiz, PhD, Meghan Pierce, PhD
- 715 ,William K. Scott, PhD, Paula Schnurr, PhD, Krista DiSano, PhD, Thor Stein, MD, PhD, Robert
- 716 Ursano, MD, Douglas E. Williamson, PhD, Erika J. Wolf, PhD, Keith A. Young, PhD.

717